Results 41 to 50 of about 96,485 (242)

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Effect of Disease Severity on the Quality of Life and Sense of Stigmatization in Psoriatics

Clinical, Cosmetic and Investigational Dermatology, 2021
Beata Kowalewska,1 Barbara Jankowiak,1 Mateusz Cybulski,1 Elżbieta Krajewska-Kułak,1 Dzmitry Fiodaravich Khvorik2 1Department of Integrated Medical Care, Medical University of Bialystok, Bialystok, Poland; 2Department of Dermatovenerology, Medical ...
Kowalewska B, Jankowiak B, Cybulski M, Krajewska-Kułak E, Khvorik DF   +4 more
doaj  

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Acta Dermato-Venereologica, 2021
Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis.
Riccardo G. Borroni, Piergiorgio Malagoli, Luigi Gargiulo , Mario Valenti, Giulia Pavia, Paola Facheris, Emanuela Morenghi, Isotta Giunipero di Corteranzo, Alessandra Narcisi, Michela Ortoncelli, Paolo Dapavo, Antonio Costanzo   +11 more
doaj   +1 more source

Korelasi Kadar TNF-α dan Skor Psoriasis Area And Severity Index (PASI) pada Pasien Psoriasis [PDF]

, 2011
Correlation of serum TNF-α levels and psoriasis area and severity index (PASI) score in psoriatic patientsBackround: Psoriasis is a chronic inflammatory disease characterized by erythematous scaly patches. Psoriasis affects ±2.5% of world population, and
Budiastuti, A. (Asih)
core  

A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index [PDF]

, 2017
Background: Actinic keratosis (AK) severity is currently evaluated by subjective assessment of patients. Objectives: To develop and perform an initial pilot validation of a new easy-to-use quantitative tool for assessing AK severity on the head ...
Arkachaisri, Benzekri, Chams-Davatchi, Chen, Chetty, Cockerell, Consensus Report of the European Task Force on Atopic Dermatitis, Feily, Fernandez-Figueras, Fredriksson, Green, Green, Ianhez, Langley, Lee, Mlynek, O'Brien, Olsen, Pandya, Röwert-Huber, Schaefer, Schmitz, Stockfleth, Taieb, Uhlenhake, Wei, Werner, Wolf   +27 more
core   +1 more source

Experimental Validation of an Immune Cell Infiltration Signature in Psoriasis: Translating Computational Modeling to In Vivo Efficacy

Journal of Clinical Laboratory Analysis, EarlyView.
We calculated the infiltration profiles of 28 immune cells within psoriatic immune microenvironment through single‐sample gene set enrichment analysis (ssGSEA) algorithm based on the eleven psoriasis related microarray datasets. Five immune‐related genes CXCL8, CXCL9, CCL18, RGS1, and SAMSN1 are associated with psoriasis, and establish a predictive ...
Tingjin Zheng, Rong Xu, Jianming Zhang, Xiujuan Wen, Hao Huang, Hongfeng Tang, Zhishan Zhang, Chong Zeng   +7 more
wiley   +1 more source

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

Dermatology and Therapy, 2023
Introduction Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO).
April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov   +6 more
doaj   +1 more source

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. [PDF]

, 2019
Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of
Lee, Erica B, Liao, Wilson, Pithadia, Deeti J, Reynolds, Kelly A, Wu, Jashin J   +4 more
core  

Real‐World, Prospective, Multicenter Outcomes to Brodalumab Treatment in Patients With Moderate‐to‐Severe Psoriasis in Greece (The RESOLVE Study)

JEADV Clinical Practice, EarlyView.
RESOLVE was a prospective, real‐world study in patients with moderate‐to‐severe psoriasis treated with brodalumab. At Week 12, 76.4% achieved PASI ≤ 3, 53.5% PASI100, and 71.5%/54.2% achieved sPGA0/1 and sPGA 0, respectively. At Week 52, 96.1% achieved sPGA success (clear/almost clear). Furthermore, at Week 52, mean DLQI scores decreased by 12.6 ± 6.2,
Electra Nicolaidou, Pantelis Panagakis, Dimitrios Xekardakis, Natalia Rompoti, Marina Papoutsaki, Ioanna Lefaki, Kanella Kalapothakou, Despina Exadactylou, Athanasios Chaniotis, Vasiliki Chasapi, Alexander Stratigos   +10 more
wiley   +1 more source

Short-term effectiveness of biologic agents in moderate-to-severe psoriasis: A real-world comparative study

Turkderm Turkish Archives of Dermatology and Venereology
Background and Design: This study aimed to comparatively evaluate the short-term effectiveness of biologic agents used in the treatment of moderate-to-severe plaque psoriasis.
Mehmet Enes Güner, Perihan Öztürk, Ozan Can Yaray, Esra Merve Evran Kılıç, Mine Müjde Kuş   +4 more
doaj   +1 more source